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Background  and  aim: Evidence  is accumulating  that  several  markers  in  the  human  leukocyte  antigen
(HLA)  region  have  been  associated  with  decreased  or increased  antibody  response  to  hepatitis  B vaccine
in  different  individuals.  This  meta-analysis  is  to  assess  the  associations  of HLA  class  II  DRB1  and  DQB1
alleles  with  immunologic  response  to hepatitis  B vaccine  in healthy  people.
Methods: A  systematic  review  of  cohort  studies  in  healthy  people  was  performed.  We  searched  databases
for  relevant  studies  that were  published  in English  or Chinese  up to February  17, 2012.  Odds  ratios
(ORs)  with  corresponding  95%  conﬁdence  intervals  (CIs)  of HLA  alleles  response  to  hepatitis  B  vaccine
were  pooled  by using  of  a ﬁxed-effects  or random-effects  model  depending  on  absence  or  presence  of
signiﬁcant  heterogeneity.  All statistical  tests  were  two-sided.
Results: Fifteen  studies  were  included  in this  meta-analysis  after  scanning  774  potentially  relevant  arti-
cles.  A  total  of 2308  subjects  (including  1215  responders,  873  nonresponders  and  220  control  populations)
were  included.  For  DRB1  alleles,  pooled  ORs  showed  that  three  HLA  variants,  DRB1*01,  DRB1*1301  and
DRB1*15  were  associated  with  a signiﬁcant  increase  antibody  response  to  hepatitis  B vaccine,  their
pooled  ORs  were  2.73,  5.94  and  2.29 respectively.  While  DRB1  *03  (DRB1*0301),  DRB1*04,  DRB1*07
and  DRB1*1302  were  opposite,  their pooled  ORs  were 0.55(0.42),  0.57,  0.24  and  0.25  respectively.  And
for  DQB1  alleles,  pooled  ORs  showed  that DQB1*05  (DQB1*0501),  DQB1*06,  DQB1*0602  were  associated
with  a signiﬁcant  increase  antibody  response  to hepatitis  B vaccine.  Their  merger  ORs  were  1.85,  2.35,
2.34  and  3.32 respectively.  While  DQB1*02  (pooled  OR =  0.27)  was adverse.  Sensitivity  and  speciﬁcity
analysis  of  HLA  alleles  showed  that  DRB1*1301and  DQB1*0602  had  high  speciﬁcity  (94.2%  and  90.1%)
but  low  sensitivity  (25.1%  and  26.3%),  respectively.
Conclusion: It was  suggested  that speciﬁc  HLA  class  II alleles  (DRB1  and  DQB1)  were  associated  with
antibody  response  to HepB.
 201©
. Introduction
Since the early1980s, hepatitis B vaccine (HepB) has been avail-
ble. Its effectiveness and safety have been proved sufﬁciently.
espite of the type/dose of vaccine, or route of administration,
bout 5%–15% of all individuals fail to seroconvert to anti-HBs
10 mIU/mL with the standard vaccination schedule [1]. Several
Abbreviations: HBV, hepatitis B virus; HLA, human leukocyte antigen; HepB,
epatitis  B vaccine; ORs, Odds ratios; CIs, conﬁdence intervals; MHC, major histo-
ompatibility complex; IHWS, International Histocompatibility Workshop.
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factors are possible to affect adversely the antibody response to
HepB including male gender, advancing age, overweight, smok-
ing, immunosuppression, and immunodeﬁciency [2]. In addition,
evidences are accumulating that several markers in the human
leukocyte antigen (HLA) region have been associated with antibody
response to HepB in different individuals [3–5].
The HLA are coded by the major histocompatibility complex
(MHC) group of genes located on chromosome six in the human
genome. HLA molecules are divided into three classes, HLA class I,
class II and class III. Among them, HLA class II molecules present
antigens from outside of the cell to T-lymphocytes. These partic-
ular antigens stimulate the multiplication of T-helper cells, which
in turn stimulate antibody-producing B-cells to produce antibod-
ies to that speciﬁc antigen. Some investigators have suggested that
Open access under CC BY-NC-ND license.several HLA class II alleles are involved in the immune response to
hepatitis B antigen. For example, individuals harbored HLA class II
allele DRB1*0701, DRB1*0301 were less likely to have a serolog-
ical response to HepB [6], while individuals harbored DRB1*1301
 license.
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Table 1
Quality criteria for the included studies.
Quality parameter Score
2 1 0
No. of cases >100 50—100 <50
Quality  control of PCR DNA sequencing or Repeat Internal control ND
HLA  control group Yes No Not scored
Explanation  of participants selected Detail Simple Unknown
Matching  of resonpenders and nonresponders
Confounder group 1 HBsAg and HBV DNA HBsAg or HBV DNA ND
Confounder  group 2 Age and sex Age or sex ND
Note: Detail: participants should be excluded with previous or active hepatitis B virus (HBV) infection, hepatitis C virus infection, HIV infection, chronic liver or kidney
disease, autoimmune disease, cancer, pregnancy or lactation and allergy to vaccine components, smoking (20/day), alcohol intake (>40 g/day), intravenous substance abuse
or  regular immunosuppressant medication; simple: participants included were negative for HBsAg, HBeAg, anti-HBc, and HBV DNA, ruled out the possibilities of previous
or  active hepatitis B virus (HBV) and other hepatitis virus injection, got rid of other chronic diseases; unknown: only healthy people without any other informations; DNA
consequence: the sequencing results were compared with the corresponding nucleotide sequences of the NCBI GenBank (BLAST); repeat: checking the result with more
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shan  one method; internal control: a gene displayed highly uniform expression in 
onditions; ND: Undetected or unknown.
ere more likely to have a serological response to HepB [6]. How-
ver, other researchers did not ﬁnd such an association [5,7]. The
nconsistence of these data might because of the sample size and
tatistical methods applied in these studies.
In this study, the meta-analysis was adopted to provide
nhanced statistical power for the interpretation of published data,
nd to generate a summary estimate of the effect of different HLA
n HepB response.
.  Methods
.1. Search strategy and selection criteria
We searched MEDLINE (1966 to February 17, 2011),
MBASE (1950 to February 17, 2011), Cochrane library
http://www.cochrane.org), China National Knowledge Infor-
ation database (1985 to February 17, 2011) and Chinese
anfang Database using the Medical Subject Heading (MeSH)
erms “Hepatitis B Vaccines,” “HLA Antigens,” “Histocompatibility
ntigens,” and the individual corresponding free terms. In addi-
ion, we performed manual searches by scanning the reference
ists of the included articles to locate additional papers related to
he topic. We  also contacted the authors of some studies when
ecessary.
The following inclusive criteria were set and reviewed by two
ndependent investigators (ZK Li and JJ Nie): (1) recombinant vac-
ine; (2) study’s method based on a cohort study design; (3) the
tudies showing interests in the association between HLA alleles
nd response to HepB (the vaccines were classiﬁed into responders
anti-HBs ≥10 IU/L) and nonresponders (anti-HBs <10 IU/L) after
he whole vaccine schedule; (4) following the standard vaccination
ith currently licensed hepatitis B recombinant vaccines (immu-
ized at 0,1,6 months or added one dose after three doses); and
5) odds ratios (ORs) in cohort studies reported with the 95% conﬁ-
ence intervals (CI) (or, if 95% CIs were not available, the reported
ata were sufﬁcient to calculate them). We  excluded the studies: (1)
ot published as a full text; (2) the numbers of included subjects
ere less than 10; (3) studies without groups of nonresponders
r with inconformity group (the value of cut-off of anti-HBs did
ot meet ours criterion); (4) the subjects were unhealthy; and (5)
eviews, not original papers. If more than one version of the same
tudy was retrieved, only the most recent published study or the
tudy with larger number of participants was used. If the earlier
aper focused on a given HLA alleles and the subsequent paper(s)
xamined additional HLA alleles by the same author in the same
tudy population, the two papers were regarded as one study [8,9].organisms during various phases of development and under different environment
2.2.  Data extraction
Data  were independently extracted and crosschecked by two
researchers (ZK Li and JJ Nie), using a standardized form. The dis-
crepancies were resolved by consensus. The following data were
collected from each study: ﬁrst author; publication year; coun-
try or area; study subjects; number of responders, nonresponders
and controls; HLA genotyping and anti-HBs detection methods;
HLA class II alleles (HLA-DRB1 and HLA-DQB1) and potential con-
founders (age, sex, HBsAg and HBV DNA).
2.3. Assessment of study quality
Two investigators (ZK Li and JJ Nie) independently rated the
quality of each retrieved study by using a 12-point scoring system
that was  designed for this meta-analysis. The scoring system was
based on factors that might affect the quality of these observational
studies (Table 1) [10], including case number, quality control of PCR,
HLA control group, explanation of participants selected and match-
ing of responders and nonresponders. Studies with an overall score
of 9 or higher were classiﬁed as high-quality studies. Those with
an overall score of 5–8 were classiﬁed as medium-quality studies.
And studies with an overall score of 4 or lower were classiﬁed low-
quality studies. A kappa identity test was  carried out to check the
consistency. Disagreement was  resolved by consensus.
2.4. Statistical analysis
The  statistical work was performed by using RevMan Manager
5.0 software (Cochrane Collaboration). Heterogeneity was  evalu-
ated by the means of X2 test, P values and I2 statistics. I2 values
of 25%, 50% and 75% were assigned as low, moderate, and high
estimates, respectively [11]. Studies were considered to have no
statistical heterogeneity when P ≥ 0.1, and a ﬁxed effect model
(Mantel–Haenszel method) was used to merge data. Studies were
considered to have heterogeneous if P < 0.1, and a random effects
mode (DerSimonian and Laird method) was used [12]. When
signiﬁcant heterogeneity was detected in the allele (number of
studies > 2), sensitivity analysis was  conducted by removing one
study at a time to evaluate whether the results were markedly
affected by a single study. Pooled odds ratios with the correspond-
ing 95% conﬁdence intervals (95% CIs) were calculated. Publication
biases were assesses by Egger’s test (STATA version 12.0) and fun-
nel plots. The criteria for Egger’s texts were requirement of at least
three or more studies. A P value of <0.05 was considered statistical
signiﬁcance.
Z.-K. Li et al. / Vaccine 31 (2013) 4355– 4361 4357
765 citations identified 
by databa se se arch and
9 citation s iden tified 
by citation l ist
774 reco rds  sc ree ned
104 full-text articles assessed for e ligib ility 
670 articles  exc luded af ter 
title and abs tract review 
(includ ing  dupl icate  stu dies)
77 articles  exc luded:
1 dupl ication o f data
2   not  rele van t to hepatitis B vacci ne or 
HLA
3 reports not  retrieved
5 not  rec ombinant vaccine 
8 non -healthy population
12 In vitr o experimen ts o r animal 
experimen ts
13 letter s or  edito rials  or  syst ematic 
revi ews or  conferenc e pape rs
27 studies included in q ualita tiv e analys is
12 articles  exc luded:
2   im mune  st rategy not  mee t the 
inclusion cr iteria
4 de tection of anti -HBs no t mee t the 
inclusion cr iteria
6 not s uit abl e for  meta-ana lysis
15 studies included in  the  meta-ana lysis
Fig. 1. Flow chart of article selection.
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y.. Results
.1. The characteristics and the rank of the included studies
We  identiﬁed 774 potentially relevant articles through search-
ng the published literature. A total of 15 articles were included in
his meta-analysis (Fig. 1). The main features of the studies included
n this meta-analysis are shown in Table 2. Of the 15 included arti-
les, 10 were from China [7–9,13–19], 4 from European [6,20–22]
nd 1 from Iran [5]. Seven studies excluded the possibility of the
ow level of HBV DNA infection leading to nonresponse through
etecting HBV DNA. Factors of age and sex were matched or tested
nsigniﬁcantly in 11 studies, others matched only one factor or not
t all. A total of 2308 (including 1215 responders, 873 nonrespon-
ers and 220 control population) subjects were enrolled in this
tudy. The most commonly reported HLA alleles associated with
esponse to HepB were HLA-DRB1 and HLA-DQB1 alleles. According
o the assessing criteria of study quality, 6 studies were classiﬁed
s high-quality studies, 6 were sorted as medium-quality studies,
nd 2 were regarded as low-quality studies. The value of kappa test
or agreement between the two raters on overall quality evalua-
ion was 0.784. Only studies published in English and Chinese were
ncluded in this meta-analysis. Ta Ch
F ( [ H H M L Z W Y L A H G Y L Q
N
o
PC en
4358 Z.-K. Li et al. / Vaccine 31 (2013) 4355– 4361
Table 3
Summary of associations between HLA alleles and response to hepatitis B vaccine, pooled odds ratios (OR) with corresponding 95% conﬁdence intervals (95% CI) of the
published results were calculated where more than one study investigated the allele.
HLA types No. of Heterogeneity Model Association with response Egger’s 2-tailed bias
Study X2 value P value I2 P value OR 95%CI P value 95%CI T value
DRB1*01 3 0.00 1.00 0 Fixed 0.0005 2.73 1.55–4.81 0.411 −121.79 to 98.74 −1.33
DRB1*03  4 1.12 0.77 0 Fixed 0.009 0.55 0.35–0.86 0.189 −32.62 to 12.22 −1.96
DRB1*0301  2 0.00 1.00 0 Fixed 0.01 0.42 0.21–0.84 ND
DRB1*04 5 0.29 0.99 0 Fixed 0.009 0.57 0.37–0.87 0.448 −21.00 to 11.99 −0.87
DRB1*07  8 16.03 0.02 56 Random <0.00001 0.24 0.14–0.43 0.155 −202.28 to 40.72 −1.63
DRB1*11  6 7.39 0.19 32 Fixed 0.12 1.42 0.91–2.22 0.785 −81.93 to 66.35 −0.29
DRB1*13  7 14.23 0.03 58 Random 0.20 1.58 0.79–3.19 0.124 −427.51 to 69.96 −1.85
DRB1*1301  3 1.51 0.47 0  Fixed <0.0001 5.94 2.65–13.32 0.777 −366.98 to 346.51 −0.36
DRB1*1302  2 1.06 0.30 5  Fixed 0.007 0.25 0.09–0.68 ND
DRB1*14 6 17.45 0.004 71 Random 0.94 1.04 0.31–3.56 0.341 −345.19 to 151.71 −1.08
DRB1*15  7 7.54 0.27 20 Fixed <0.00001 2.29 1.61–3.27 0.949 −29.54 to 31.13 0.07
DQB1*02  4 5.30 0.15 43 Fixed <0.00001 0.28 0.18–0.42 0.327 −40.31 to 21.75 −1.29
DQB1*03  4 0.91 0.82 0 Fixed 0.24 1.27 0.85–1.91 0.956 −2.96 to 3.04 0.06
DQB1*0301  2 0.44 0.51 0 Fixed 0.93 1.02 0.59–1.77 ND
DQB1*0302 3 5.09 0.08 61 Random 0.52 0.74 0.29–1.88 0.475 −2402.69 to 2025.52 −1.08
DQB1*0303  3 0.02 0.99 0 Fixed 0.19 1.91 0.72–5.05 0.475 −2402.69 to 2025.52 −1.08
DQB1*04  4 1.98 0.58 0 Fixed 0.94 0.97 0.39–2.40 0.472 −1100.87 to 727.09 −0.88
DQB1*05  4 0.65 0.88 0 Fixed 0.008 1.85 1.17–2.93 0.029 2.67 to 18.92 5.72
DQB1*0501  2 0.22 0.64 0 Fixed 0.03 2.35 1.09–5.05 ND
DQB1*0503 2 2.59 0.11 61 Fixed 0.98 1.02 0.23–4.51 ND
DQB1*06 4 7.76 0.05 61 Random 0.03 2.34 1.09–5.01 0.529 −38.23 to 26.83 −0.75
DQB1*0602  3 0.20 0.91 0 Fixed 0.0001 3.32 1.80–6.15 0.917 −225.53 to 220.91 −0.13
DQB1*0603  2 3.79 0.05 74 Random 0.44 1.92 0.36–10.24 ND
0.45 
N igniﬁc
3
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c
3
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l
D
h
(
s
w
tDQB1*0604 3 6.15 0.05 67 Random 
ote: ND: not performed when there is less than three studies; Bold line indicates s
.2. Association of HLA-DRB1 alleles with antibody response to
epB
Eight  two-digit numbering of HLA-DRB1 alleles were included in
he meta-analysis as shown in Table 3, and the four-digit number-
ng of DRB1*03, DRB1*13 alleles are also listed in Table 3. Signiﬁcant
eterogeneity were observed in three alleles (DRB1*07, DRB1* 13,
RB1*14), and these alleles were moderate heterogeneity. Pooled
Rs showed that three HLA variants (DRB1*01, DRB1*1301 and
RB1*15) were associated with a signiﬁcant increase of antibody
esponse to HepB, while DRB1 *03 (DRB1*0301), DRB1*04, DRB1*07
nd DRB1*1302 were associated with a signiﬁcant decrease of anti-
ody response to HepB. Statistically signiﬁcant publication bias was
ot found in other DRB1 alleles. The funnel plots were symmetri-
al. The publication bias of DRB1*0301 and DRB1*1302 could not
e performed due to the insufﬁcient numbers of articles (less than
hree studies).
The  results of sensitivity analysis for alleles with signiﬁcant het-
rogeneity are shown in Table 4. Two studies (Gong et al. [16] and
hang et al. [7]) were responsible for the heterogeneity of DRB1*07,
he study of Hohler et al. [6] was the source of the heterogeneity of
RB1*13, and the study of Zhang et al. [7] led to the heterogeneity
or DRB1*14. The statistical results did not change after removing
orresponding studies.
.3.  Association of HLA-DQB1 alleles with antibody response to
epB
Five  two-digit numbering of HLA-DQB1 alleles were included
n the meta-analysis as shown in Table 3, and the four-digit
umbering of DQB1*03, DQB1*05 and DQB1*06 alleles are also
isted in Table 3. Signiﬁcant heterogeneity of DQB1*0302 and
QB1*06 (DQB1*0603 and DQB1*0604) was observed. These alleles
ad moderate heterogeneity. Pooled ORs showed that DQB1*05
DQB1*0501) and DQB1*06 (DQB1*0602) were associated with a
igniﬁcant increase of antibody response to HepB, while DQB1*02
ere associated with a signiﬁcant decrease of antibody response
o HepB. By using Egger’s test, statistically signiﬁcant publication0.52 0.10–2.80 0.600 −1067.92 to 1197.53 0.73
ant association.
bias  was  found in DQB1*05. The publication biases of DQB1*0301,
DQB1*0501, DQB1*0503 and DQB1*0603 could not be performed
because of the insufﬁcient numbers of articles (less than three stud-
ies).
The results of sensitivity analysis were shown in Table 4. Two
studies (Lango-Warensjo et al. [21] and Mcdermott et al. [22]) were
responsible for the heterogeneity of DQB1*0302 and DQB1*0604.
And the study of Amirzargar et al. [5] led to the heterogeneity
of DQB1*06. The statistical results of DQB1*0302 and DQB1*0604
were not applicable for heterogeneity. The statistical results of
DQB1*06 did not change after removing corresponding studies in
sensitivity analysis.
3.4.  The subgroup analysis based on different ethnic
Considering the possibility that ethnic difference might affect
the response to HepB [23,24]. HLA alleles associated with
response to HepB were analyzed in different ethnicity subgroups
as follows. Considering the number of references and sam-
ples, DRB1*03, DRB1*04, DRB1*07, DRB1*11, DRB1*13, DRB1*14,
DRB1*15, DQB1*02, DQB1*03, DQB1*04, DQB1*05 and DQB1*06
alleles were included in the subgroup analysis. The results
showed that DRB1*03, DRB1*04, DRB1*11, DQB1*02, DQB1*05 and
DQB1*06 were statistical signiﬁcant in Caucasian group, but not
in Asian ethnicity. However, the result of DRB1*15 was  adverse
with the above alleles. In addition, in both races, the same statis-
tically signiﬁcant results were observed in the alleles of DRB1*07,
DRB1*13, DRB1*14, DQB1*03 and DQB1*04. The OR values did not
change (OR > 1 or <1) in the alleles with statistical signiﬁcance in
subgroup analysis. So ethnicity was an important factor to inﬂuence
the response to HepB in the genetic analysis, which is consistent
with some researches [25–27].
3.5. Sensitivity and speciﬁcity of HLA alleles in healthy population
for the prediction of response to HepB
The sensitivity and speciﬁcity analysis of HLA alleles
above mentioned in healthy population were applied for the
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Table 4
Results of sensitivity analysis.
Alleles Origin of heterogeneity OR (95%CI) P value for OR P value for heterogeneity text I2
DRB1*07 Gong et al. [16], Zhang et al. [7] 0.25 (0.17–0.37) <0.00001 0.59 0
DRB1*13  Hohler et al. [6] 1.14 (0.74–1.76) 0.55 0.80 0
DRB1*14  Zhang et al. [7] 1.85 (1.00–3.45) 0.05 0.31 16
DQB1*0302  Lango-Warensjo et al. [21] NA
Mcdermott  et al. [22]
DQB1*06 Amirzargar et al. [5] 1.84 (1.18–2.89) 0.008 0.39 0
N
p
D
D
a
i
s
t
s
b
r
4
i
c
t
T
SDQB1*0604  Lango-Warensjo et al. [21] Mcdermott et al. [22] NA
A: not applicable for heterogeneity.
rediction of response to HepB. We  evaluated the frequencies of
RB1*01, DRB1*03, DRB1*0301, DRB1*04, DRB1*07, DRB1*1301,
RB1*1302, DRB1*15, DQB1*02, DQB1*05, DQB1*0501, DQB1*06
nd DQB1*0602 (which were proved to be statistically signif-
cant in Table 3) alone using data extracted from all included
tudies as potential biomarkers for the prediction of response
o HepB. Among them, DRB1*1301 and DQB1*0602 had high
peciﬁcity (94.2% [95% CI = 90.3–98.1], 90.1% [95% CI = 85.3–94.9]),
ut low sensitivity (25.1% [95% CI = 18.5–31.7], 26.3% [20.6–32.0],
espectively) (Table 5).
. DiscussionHLA associations with response to HepB have been intensively
nvestigated across the global populations [28]. Hohler et al. [29]
onducted a study on 202 twin pairs indicating that genetic fac-
ors might account for nearly 60% of immune responsiveness to
able 5
ensitivity and speciﬁcity of HLA alleles in healthy population for the prediction of respo
HLA alleles Responders Nonresponders 
DRB1*01
Positive 56 21 
Negative 160 150
DRB1*03
59  63 
248 116
DRB1*0301
20  34 
79 51
DRB1*04
73  74 
254 125
DRB1*07
76  141 
658 376
DRB1*1301
42  8 
125 130
DRB1*1302
7  14 
107 51
DRB1*15
141  53 
442  389
DQB1*02
104  105 
219  54
DQB1*05
131  35 
192  124
DQB1*0501
39  11 
76 54
DQB1*06
130  47 
193 146
DQB1*0602
61  15 
171 136HepB, of which HLA genes were the major contributors. We  have
attempted to review the published literatures with the purpose
of identifying common HLA allele affecting the antibody response
of HepB. Our systematic meta-analysis showed that DRB1 *03
(DRB1*0301), DRB1*04, DRB1*07, DRB1*1302 and DQB1*02 were
associated with nonresponse to HepB, while DRB1*01, DRB1*1301,
DRB1*15, DQB1*05 (DQB1*0501) and DQB1*06(DQB1*0602) were
associated with a signiﬁcant increase of antibody response to
HepB. For the sake of evaluating the predicted value of above
described alleles, the analysis of sensitivity and speciﬁcity of these
alleles were carried out. The results shown that DRB1*1301 and
DQB1*0602 had high speciﬁcity to predicting the antibody response
to HepB, but all of these alleles had low sensitivity to predicting the
antibody response to HepB. Because single HLA allele was not suit-
able as a predictive value, HLA haplotypes might be a more suitable
tool. However, all discussions regarding the HLA haplotypes were
based on designations according to the most probable combina-
nse to hepatitis B vaccine.
Sensitivity, % (95% CI) Speciﬁcity, % (95% CI)
25.9 (20.1–31.7) 87.7 (82.8–92.6)
19.2 (14.8–23.6) 64.8 (57.8–71.8)
20.2 (12.2–28.2) 60.0 (49.6–70.4)
22.3 (17.8–26.8) 62.8 (56.1.0–69.5)
10.2 (8.0–12.4) 72.7 (68.9–76.5)
25.1 (18.5–31.7) 94.2 (90.3–98.1)
6.1 (1.7–10.5) 78.5 (68.5–88.5)
24.2 (20.7to 27.7) 88.0 (85.0–91.0)
31.2 (26.2–36.2) 34.0 (26.6–41.4)
40.6 (35.2–46) 78.0 (71.6–84.4)
33.9 (25.2–42.6) 83.1 (74–92.2)
40.2 (34.9–45.5) 75.6 (69.5–81.7)
26.3 (20.6–32.0) 90.1 (85.3–94.9)
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ions [30]. It is difﬁcult to conduct the meta-analysis of haplotypes
ue to different combination among studies. Establishment of the
xact haplotypes by family studies is needed in the future.
Only  the two-digit numbering and the four-digit numbering
f alleles were included in our study because the ﬁfth and sixth
igits (silent substitutions) were not expected to alter the antigenic
xpression [31]. And through this meta-analysis, we also found that
RB1*1301 and 1302 had opposite effect on the response to HepB,
hich was agreed with the previous report [21]. There was only one
mino acid difference at allele 86 in the peptide-binding groove. At
his position, DRB1*1301 has a Val, while DRB1*1302 has a Gly, and
he single position change maybe has an important inﬂuence on
BsAg production [21]. Therefore, compared with two-digit num-
ering of alleles, four-digital numbering of HLA alleles will be more
recious for analysis the relationship between HLA and response
o HepB.
According to our quality assessment criteria, both the studies
f Hohler et al. [20] and Hu et al. [14] were regarded as low-
uality studies. These two  studies were excluded when analyzing
he alleles of DRB1*01, DRB1*04, DRB1*07, DRB1*11, DRB1*14,
RB1*15 and DQB1*04. The statistical results did not change after
xcluding these studies, the adjusted pooled odds ratio was much
he same. The causes could be that the assessment criteria of
 cross-sectional study were not admitted by the great mass of
esearchers, our assessment criteria were established based on the
rofessional knowledge, some related reports and the demand of
ur paper. So the so-called low quality studies did not really reﬂect
he quality of study. However, the study assessment was  neces-
ary, which can make clear the study for the people from different
anguage countries. In addition, high quality studies were represen-
ative of good design, clear background, and strict quality control.
The  shape of funnel plot and Egger’s test indicated that the pub-
ication bias might exist in some HLA alleles. And the result of
ensitivity analysis for alleles with signiﬁcant heterogeneity con-
inced the existence of publication bias. The source of bias might
e due to editors more ready to forgive authors for ﬂaws in study
esign when statistically signiﬁcant associations were reported.
oor methodological quality of smaller studies, or control group
ould not be truly representative of the HLA frequency in the
ocality. So control group was necessary to be set for testing repre-
entative of HLA frequencies through comparing with frequencies
ublished by International Histocompatibility Worshop (IHWS).
Our  study included 2308 subjects (1215 responders, 873 non-
esponders and 220 control population). Sample collection of
onresponders is practically difﬁcult, so the statistical power is
ow due to small sample size in a single study. However, the meta-
nalysis can provide enhanced statistical power for integrating the
ublished data. Moreover, our meta-analysis tried to make assess-
ent of study quality, which was seldom found in similar analysis.
he subjects included in our paper were healthy populations, and
he confounder factors were managed strictly.
The limitation of this paper was the small numbers of included
tudies, so the ethnic subgroup analysis was difﬁcult to evaluate
n some alleles. Another limitation was only single allele analyzed
n this study. HLA allele distribution may  be inﬂuenced by linkage
isequilibrium of genes and interactions between different alleles,
o the multicenter studies and haplotypes analysis are needed in
he future study.
Production of anti-HBs antibody following vaccination or nat-
ral infection is helper T cell dependent. CD4+ T lymphocytes
ecognize different epitopes within the HBsAg molecule that can be
resented by certain HLA class II antigens [32]. Despite conﬂicting
ndings from previous studies, this meta-analysis strengthens
he case that HLA class II alleles are associated with an immune
esponse to HB vaccine, which is helpful to explore the mechanism
f failing to response to HepB. Moreover, our study also provided
[
[ (2013) 4355– 4361
some  suggestion for future studies who  concentrate on efﬁcacy of
hepatitis B vaccine that Certain HLA class II types should be consid-
ered in the study of antibody nonresponse.
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